Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Survivor: Novo Nordisk Sets Levemir Apart Amid Synthetic Insulin Scare

Executive Summary

There will be winners and losers for the makers of type 2 diabetes drugs as doctors and patients absorb news of a potentially higher cancer risk for Sanofi-Aventis' long-acting insulin Lantus. Not surprisingly, Novo Nordisk is working hard to come out on top in any shakeout and held a recent presentation to make its case to investors

You may also be interested in...



Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data

Despite early evidence that one of its experimental diabetes drugs may cause higher heart and blood pressure rates, Eli Lilly remains adamant that development should continue

Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data

Despite early evidence that one of its experimental diabetes drugs may cause higher heart and blood pressure rates, Eli Lilly remains adamant that development should continue

Lilly Stands By Experimental Diabetes Drug, Despite Questions About Data

Recent data showing faster heart and blood pressure rates lead some analysts to question the drug maker's strategy for its diabetes drug.

Related Content

Topics

UsernamePublicRestriction

Register

OM013658

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel